Filter
43
Featured
Recommendations
9
Language
Document type
Guidelines
30
Studies & Reports
7
Fact sheets
4
Infographics
1
No document type
1
Countries / Regions
South Africa
1
East and Southern Africa
1
Authors & Publishers
Publication Years
Category
Clinical Guidelines
2
Countries
1
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention overall, as it allows people to choose a method that they prefer.
In this guideline, WHO recommends an offering long-acting injectable lenacapavir (LEN
...
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex C
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex D
Mathematical modelling of lenacapavir: landscaping review on impact and cost–effectiveness
recommended
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex E
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex F
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex G Abstract
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment.
Herramienta de estimación de necesidades y costos de la profilaxis preexposición (PrEP). Instruccciones de uso. En particular, calcula 1) el número de personas que se beneficiarían de la PrEP, en cada población relevante; 2) el total de personas que el país o entidad tiene capacidad para cubri
...
This technical brief aims to support these trends, accelerated by the COVID-19 pandemic, and improve PrEP uptake, persistence, and effective use by providing implementation guidance for differentiated and simplified service delivery. The brief aims to support a range of stakeholders in planning and
...
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at red
...
Adolescent girls and young women (AGYW) remain disproportionately affected by HIV in Eastern and Southern Africa (ESA), with 26 per cent of new infections attributed to this population. AGYW face many personal, social and structural barriers to access, uptake and use of traditional HIV prevention me
...
July 2021. This publication brings together important clinical and programmatic updates produced by WHO since 2016 and provides comprehensive, evidence-informed recommendations and good practice statements within a public health, rights-based and person-centred approach.
These guidelines bring in
...
Accessed: 29.02.2020
